CN1241942C - 使用胰岛素的肽类似物治疗糖尿病的方法 - Google Patents

使用胰岛素的肽类似物治疗糖尿病的方法 Download PDF

Info

Publication number
CN1241942C
CN1241942C CNB998042765A CN99804276A CN1241942C CN 1241942 C CN1241942 C CN 1241942C CN B998042765 A CNB998042765 A CN B998042765A CN 99804276 A CN99804276 A CN 99804276A CN 1241942 C CN1241942 C CN 1241942C
Authority
CN
China
Prior art keywords
peptide analogs
chain
residue
peptide
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998042765A
Other languages
English (en)
Chinese (zh)
Other versions
CN1294597A (zh
Inventor
A·高尔
N·凌
P·J·康伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of CN1294597A publication Critical patent/CN1294597A/zh
Application granted granted Critical
Publication of CN1241942C publication Critical patent/CN1241942C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CNB998042765A 1998-02-23 1999-02-23 使用胰岛素的肽类似物治疗糖尿病的方法 Expired - Fee Related CN1241942C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2815698A 1998-02-23 1998-02-23
US09/028,156 1998-02-23

Publications (2)

Publication Number Publication Date
CN1294597A CN1294597A (zh) 2001-05-09
CN1241942C true CN1241942C (zh) 2006-02-15

Family

ID=21841884

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998042765A Expired - Fee Related CN1241942C (zh) 1998-02-23 1999-02-23 使用胰岛素的肽类似物治疗糖尿病的方法

Country Status (20)

Country Link
US (1) US6197926B1 (https=)
EP (1) EP1056776A1 (https=)
JP (1) JP2002504491A (https=)
KR (1) KR20010041238A (https=)
CN (1) CN1241942C (https=)
AP (1) AP2000001888A0 (https=)
AU (1) AU741037B2 (https=)
BR (1) BR9908178A (https=)
CA (1) CA2321929A1 (https=)
EA (1) EA003944B1 (https=)
HU (1) HUP0100928A3 (https=)
ID (1) ID26788A (https=)
IL (1) IL137904A0 (https=)
NO (1) NO20004198L (https=)
NZ (1) NZ506447A (https=)
OA (1) OA11453A (https=)
PL (1) PL342517A1 (https=)
SK (1) SK12412000A3 (https=)
TR (1) TR200003048T2 (https=)
WO (1) WO1999042482A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562942B1 (en) * 1999-02-23 2003-05-13 Neurocrine Biosciences, Inc. Methods for treatment of diabetes using peptide analogues of insulin
CN1125081C (zh) * 1999-09-08 2003-10-22 中国科学院上海生物化学研究所 重组天然和新型人胰岛素及其制备方法
WO2001085154A2 (en) * 2000-05-12 2001-11-15 Oregon Health Sciences University Method of treating immune pathologies with low dose estrogen
US7462486B2 (en) * 2000-05-12 2008-12-09 Oregon Health & Science University Methods of selecting T cell receptor V peptides for therapeutic use
US20020103131A1 (en) * 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
US20070172453A1 (en) * 2002-08-30 2007-07-26 Vincent Geenen Tolerogenic approach for type 1 diabetes
US20040138116A1 (en) * 2002-08-30 2004-07-15 Vincent Geenen Tolerogenic approach for type 1 diabetes
US8987263B2 (en) 2002-10-10 2015-03-24 Meir Shinitzky Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
CA2527830A1 (en) * 2003-06-02 2004-12-23 Mercia Pharma, Inc. Therapeutic vaccine compositions for the treatment of type 1 diabetes
US8053197B2 (en) * 2004-07-30 2011-11-08 Oregon Health & Science University Methods for detecting and treating autoimmune disorders
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
DE102008003566A1 (de) * 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
MY152979A (en) 2008-01-09 2014-12-15 Sanofi Aventis Deutschland Novel insulin derivatives having an extremely delayed time-action profile
EP2249853A4 (en) 2008-01-30 2012-12-26 Univ Indiana Res & Tech Corp ESTER BASED PEPTIDE PRODRUGS
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
JP5789515B2 (ja) * 2008-12-19 2015-10-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン類似体
AU2009335715B2 (en) 2008-12-19 2016-09-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
US12370251B2 (en) 2009-11-05 2025-07-29 Mercia Pharma, Inc. Adjuvanted nanoparticulate influenza vaccine
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
MY180661A (en) 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
US20110311536A1 (en) * 2010-06-11 2011-12-22 Dana-Farber Cancer Institute, Inc. Prevention of type 1 diabetes by treg vaccination with an insulin mimetope
JP5969469B2 (ja) 2010-06-16 2016-08-17 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン受容体に対して高い活性を示す単鎖インスリンアゴニスト
EP2585102B1 (en) 2010-06-24 2015-05-06 Indiana University Research and Technology Corporation Amide-based insulin prodrugs
PL2611458T3 (pl) 2010-08-30 2017-02-28 Sanofi-Aventis Deutschland Gmbh Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
BR112014015156A2 (pt) 2011-12-20 2020-10-27 Indiana University Research And Technology Corporation análogos de insulina à base de ctp, seus métodos de produção e uso no tratamento de hiperglicemia, bem como sequência de ácido nucleico e célula hospedeira
EP3395358B1 (en) 2012-09-26 2019-11-06 Indiana University Research and Technology Corporation Insulin analog dimers
JP6538645B2 (ja) 2013-03-14 2019-07-03 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン‐インクレチン複合物
JP6701208B2 (ja) 2014-09-24 2020-05-27 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション 脂質化アミド系インスリンプロドラッグ
CN108271356A (zh) 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN111925420B (zh) * 2019-12-11 2022-04-01 山东大学 一种多肽作为嗅觉受体Olfr109激动剂配体的应用
USD1043348S1 (en) * 2021-09-24 2024-09-24 H.J. Heinz Company Brands Llc Bottle

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008241A (en) * 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5559094A (en) * 1994-08-02 1996-09-24 Eli Lilly And Company AspB1 insulin analogs
US5594100A (en) * 1995-02-22 1997-01-14 Regents Of The University Of Colorado Epitope for prevention of type I diabetes
EP0835129B1 (en) * 1995-06-30 2003-10-29 Novo Nordisk A/S Prevention of a disease having the characteristics of diabetes

Also Published As

Publication number Publication date
SK12412000A3 (sk) 2002-05-09
EP1056776A1 (en) 2000-12-06
BR9908178A (pt) 2002-01-15
US6197926B1 (en) 2001-03-06
WO1999042482A1 (en) 1999-08-26
HUP0100928A3 (en) 2001-11-28
OA11453A (en) 2003-12-08
JP2002504491A (ja) 2002-02-12
HUP0100928A2 (hu) 2001-08-28
TR200003048T2 (tr) 2000-12-21
KR20010041238A (ko) 2001-05-15
NO20004198L (no) 2000-10-20
AU2783199A (en) 1999-09-06
CN1294597A (zh) 2001-05-09
AP2000001888A0 (en) 2000-09-30
ID26788A (id) 2001-02-08
EA003944B1 (ru) 2003-10-30
CA2321929A1 (en) 1999-08-26
NO20004198D0 (no) 2000-08-22
IL137904A0 (en) 2001-10-31
PL342517A1 (en) 2001-06-18
EA200000872A1 (ru) 2001-02-26
NZ506447A (en) 2002-11-26
AU741037B2 (en) 2001-11-22

Similar Documents

Publication Publication Date Title
CN1241942C (zh) 使用胰岛素的肽类似物治疗糖尿病的方法
JP6552106B2 (ja) 糖尿病を処置するためのモダリティの組み合わせ
US20060034864A1 (en) Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
CN1188485A (zh) 胰高血糖素样肽-2及其治疗应用
CN1129224A (zh) 类胰高血糖素促胰岛素的多肽类似物组合物及其使用方法
CN1469883A (zh) 肽选择方法
HUT77047A (hu) Szklerózis multiplex kezelésére szolgáló készítmények és kezelések
CN1625564A (zh) 来源于髓鞘碱性蛋白的耐受原性肽
CN107530404A (zh) 1型糖尿病自身免疫的免疫调节治疗
KR20150005904A (ko) 강력한 작용제 효과를 지닌 신규한 ｇｈ-ｒｈ 유사체
CN1124283C (zh) 一种肽、一种支气管扩张剂,和一种血流促进剂
CN1230195A (zh) 免疫定向治疗
AU2605097A (en) Cyclic peptide vaccines for treatment and prevention of diabetes
US6562942B1 (en) Methods for treatment of diabetes using peptide analogues of insulin
CN1379786A (zh) 用于免疫治疗的修饰肽和肽类似物
CN1246125A (zh) 含有特异于胶原ⅱ的t细胞表位的肽
AU781405B2 (en) Methods for treatment of diabetes using peptide analogues of insulin
EP4081531B1 (en) A composition comprising s-arrestin peptides
CZ20003065A3 (cs) Peptidové analogy insulinu a jejich využití pro léčení diabetes mellitus
JP2000229997A (ja) 環状ペプチド及びエイズワクチン
CN1329922A (zh) C肽联合胰岛素治疗糖尿病并发症及c肽专一性抗体
MXPA00008268A (en) Methods for treatment of diabetes using peptide analogues of insulin
HK1022920A (en) Immune direction therapy

Legal Events

Date Code Title Description
BB1A Publication of application
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee